Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

Abstract Doublecortin‑like kinase 1 (DCLK1) has been identified as a novel biomarker of
cancer stem cells among several different cancer types, including colon, breast, pancreas …

The oncogenic fusion protein BCR-ABL is the driving force of leukemogenesis in chronic
myeloid leukemia (CML). Despite the great advance in CML treatment through the …

The present work deals with the synthesis, characterization, and pharmaceutical potential
evaluation of new biologically active Mn (II) and Cu (II) complexes with Schiff bases derived …

Natural products have offered a number of exciting approaches in cancer treatment over the
years. In this study, we investigated the prophylactic and therapeutic effects of the …

An efficient atom-economical synthetic protocol to access new imidazole-based N-
phenylbenzamide derivatives is described. A one-pot three-component reaction was utilized …

Abstract Chronic Myeloid Leukemia (CML) is characterized by chromosomal aberrations
involving the fusion of the BCR and ABL genes on chromosome 22, resulting from a …

Protein phosphorylation plays an important role in cellular pathways, including cell cycle
regulation, metabolism, differentiation and survival. The protein kinase superfamily network …

Simple Summary The introduction to clinical practice of a treatment-free remission approach
in chronic myeloid leukemia patients with a stable deep molecular response highlighted …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a BCR-ABL
fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation …